Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Synthon (rights of glatiramer acetate)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

The commercialization rights of glatiramer acetate in the United States. It is a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Other Business Products and Services
Acquirer
Primary Office
  • P.O. Box 110487
  • Research Triangle Park
  • Durham, NC 27709
  • United States

Synthon (rights of glatiramer acetate) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Synthon (rights of glatiramer acetate)‘s full profile, request access.

Request full access to PitchBook